Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. develops and commercializes biopharmaceutical therapies focused on neurodegenerative diseases, rare diseases and adjacent specialty areas. Company news commonly covers Alzheimer’s disease therapy LEQEMBI with Eisai, spinal muscular atrophy treatment SPINRAZA, Friedreich’s ataxia therapy SKYCLARYS, postpartum depression therapy ZURZUVAE, ALS therapy QALSODY, multiple sclerosis products and CD20 collaboration revenue tied to Roche-partnered medicines.
Recurring updates include FDA review activity, supplemental biologics license applications, global regulatory status, clinical development programs, collaboration and licensing economics, asset-rights transactions and product demand trends. Biogen news also includes financial results, acquired in-process research and development expense, governance changes and corporate-status disclosures typical of a Nasdaq-listed biotechnology issuer.
Synapticure has launched a nationwide virtual ataxia care program, offering adults living with ataxias access to movement-disorder–trained neurologists, genetic counseling, and longitudinal care through a virtual, multidisciplinary model. The program aims to shorten the often years-long journey to specialized neurological evaluation and ongoing management.
According to Synapticure, the company partnered with Biogen (Nasdaq: BIIB) to support disease education and awareness around this new resource, addressing gaps in access for the ataxia community. Biogen is not involved in developing, administering, or being responsible for Synapticure’s healthcare services or patient care. The program, led by Director of Movement Disorders Dr. Elizabeth Ferluga, offers virtual evaluations, at-home genetic testing where appropriate, coordinated workup for acquired causes of ataxias, evidence-based treatment discussions, education about clinical trials, therapy coordination, and behavioral health and caregiver support, while complementing patients’ existing care teams.
Biogen (Nasdaq: BIIB) announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. He will join Biogen’s Executive Committee, report to President and CEO Christopher A. Viehbacher, and oversee the company’s global legal and compliance functions.
Parini brings over 20 years of senior legal and strategic leadership in biopharma. He most recently served as CEO of Spur Therapeutics, where he helped transform the company and advance a rare disease program from pre-clinical to Phase 3 development. Previously at Vertex Pharmaceuticals, he rose to Chief Administrative, Legal and Business Development Officer, overseeing multiple corporate functions and contributing to acquisitions of Exonics Therapeutics and Semma Therapeutics, as well as market access agreements for cystic fibrosis medicines in several countries. Earlier, he held senior legal roles at Pfizer, including Chief Litigation Counsel, and holds J.D. and B.A. degrees from Georgetown University.
Biogen (Nasdaq: BIIB) and Eisai reported interim real‑world results from the three‑year LEADER Study of LEQEMBI in early Alzheimer’s disease at AAIC 2026. Among 427 evaluable U.S. patients treated for an average of 17 months, 82.5% remained stable or improved in disease stage, with 75.9% stable and 6.6% improving from mild dementia to MCI. Nearly 87% chose to remain on treatment. Benefits were reported as consistent across sex, race, ethnicity and APOE genotype, including APOE ε4 heterozygotes and homozygotes. In a subgroup on once‑every‑four‑weeks IV maintenance dosing, about 81% remained stable or improved; 12 of 14 on weekly SC maintenance stayed stable. ARIA occurred in 12.3% overall, mostly asymptomatic and mild, and safety observations were described as consistent with the U.S. FDA‑approved label, including in patients using antithrombotic therapy.
Biogen (Nasdaq: BIIB) reported detailed Phase 2 CELIA results for diranersen, an investigational antisense oligonucleotide targeting tau, in early Alzheimer’s disease. At 18 months, all studied doses showed efficacy on multiple prespecified cognitive and composite endpoints versus placebo, with the 60 mg every six months dose showing the strongest effects.
According to Biogen, the 60 mg regimen slowed decline by 0.54 points (26%) on CDR-SB, 42% on ADAS-Cog13, 50% on MMSE, 30% on modified iADRS, and 23% on ADCOMS, with most differences nominally significant. Diranersen achieved robust target engagement, producing mean 50–65% reductions in CSF total tau and PET-detected brain tau decreases across regions. The primary endpoint of a dose response on CDR-SB was not met, and no separation from placebo was seen on ADCS-ADL-MCI at 18 months. Diranersen was generally well tolerated, without anticipated amyloid-related imaging abnormalities, and Biogen plans to advance it into confirmatory Phase 3 development.
Biogen (Nasdaq: BIIB) and Eisai announced that the FDA has approved a supplemental Biologics License Application for LEQEMBI IQLIK (lecanemab-irmb), a once‑weekly 500 mg subcutaneous autoinjector regimen as an initiation dose for adults with early Alzheimer’s disease (mild cognitive impairment or mild dementia).
The regimen uses two 250 mg injections (~15 seconds each) and may transition after 18 months of IV or SC therapy to 360 mg weekly maintenance. Clinical data from Clarity AD long‑term extension sub‑studies showed SC exposure equivalent to IV, supporting similar efficacy and amyloid removal, with an overall safety profile generally comparable to IV and mostly localized injection reactions.
LEQEMBI IQLIK is the only at‑home administration option across the full treatment journey in the U.S., with U.S. availability for initiation dosing expected in late August 2026 via specialty pharmacies, alongside support from the LEQEMBI Companion program and Eisai’s Patient Assistance Program.
Stoke Therapeutics (Nasdaq: STOK) announced the appointment of Thomas McCauley, Ph.D., as Chief Scientific Officer. McCauley brings more than 25 years of experience building R&D organizations, advancing novel technology platforms, and translating early research into approved medicines for severe and rare diseases, including genetic medicines at Shire.
He will lead Stoke’s scientific strategy and leverage its proprietary RNA medicines platform to expand and advance the pipeline, including the lead investigational medicine zorevunersen, which is in late-stage development as a potential first-in-class, disease-modifying treatment for Dravet syndrome. McCauley previously held senior scientific leadership roles at Neptune Bio, Omega Therapeutics, Macrolide Pharmaceuticals, Translate Bio, and others.
Biogen (Nasdaq: BIIB) and Eisai reported new clinical and real‑world data at AAIC 2026 showing that the once‑weekly 500 mg LEQEMBI (lecanemab) subcutaneous autoinjector (SC‑AI) achieved drug exposure bioequivalent to the approved IV initiation regimen (10 mg/kg every two weeks), with an exposure ratio of 104% (90% CI: 99.1%–109%).
The companies said amyloid removal, clinical efficacy (CDR‑SB) and ARIA‑E incidence were driven by exposure, not administration route, supporting expectations of comparable efficacy and safety across body‑weight groups and enabling a fixed‑dose regimen. Safety for SC‑AI was generally aligned with IV, with low anti‑drug antibody incidence (1.4%) and no neutralizing antibodies observed.
Early real‑world and clinical‑practice data from two U.S. centers showed slower cognitive decline versus a matched natural‑history cohort, high patient and care‑partner satisfaction (75%–97%), strong convenience scores (83%–97%), and 92%–100% willingness to recommend treatment. Subcutaneous initiation and maintenance may allow flexible switching between IV and SC dosing and at‑home administration, pending FDA approval.
Stoke Therapeutics (Nasdaq:BIIB) completed enrollment of 162 patients in the global Phase 3 EMPEROR study of investigational Dravet syndrome therapy zorevunersen. About 50 patients have reached the 28-week primary endpoint time point and no patients have discontinued treatment.
Stoke plans to begin a rolling U.S. NDA submission in Q1 2027, with Phase 3 data expected in Q3 2027 to support completion of the NDA in the second half of 2027 and a potential U.S. launch by early 2028.
Biogen (Nasdaq:BIIB) will present new data from its Alzheimer’s disease portfolio at AAIC 2026, July 12–15 in London.
Key sessions include Phase 2 CELIA clinical, biomarker and safety data for tau‑targeting ASO diranersen, and multiple presentations on lecanemab/LEQEMBI, including subcutaneous use and three‑year LEADER real‑world evidence.
Biogen (Nasdaq: BIIB) agreed to acquire private biotech RayThera for up to $1 billion, combining an upfront payment with clinical and regulatory milestone payments. RayThera adds multiple anti-inflammatory immunology assets, with the lead candidate expected to enter Phase 1 in early Q3 2026.
Closing is targeted for Q3 2026, subject to customary regulatory approvals. After completion, Biogen plans to lead development, manufacturing and global commercialization of RayThera’s portfolio, aiming to expand into additional immune-mediated indications.